Addressing Unmet Needs in the Management of AML: From Testing to Targeted Therapy

Icahn School of Medicine at Mount Sinai
H

Integrating Targeted Therapies in AML

By Icahn School of Medicine at Mount Sinai FEATURING Hagop Kantarjian
By Icahn School of Medicine at Mount Sinai FEATURING Hagop Kantarjian
357 views
May 31, 2024
0 Comments
Login to view comments. Click here to Login
06:30
Insights from 2024 EHA Annual Meeting

EHA 2024 Insights: QuANTUM-First Trial - Newly Diagnosed FLT3-ITD+ A…

Feat. E. Oliva
23:51
Vanderbilt University Medical Center (VUMC)

Pre-Transplant Management of High-Risk AML

Feat. K. Fedorov
14:58
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Optimal Treatment Strategies for Younger P…

Feat. C. McMahon
21:05
2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "The Art and Science of Caring for Older Ad…

Feat. K. Poh Loh
35:15
SOHO Highlights: State of the Art and Next Questions

State of the Art and Next Questions: AML

Feat. F. Ravandi
35:08
MyCancerHaven

Experts Discuss the Role of Stem Cell Transplant in AML

Feat. R. Vij, M. Qazilbash
20:40
Rush University Medical Center

What is New in AML: Risk Classification, Germline Mutations, and Tar…

Feat. E. Atallah
04:16
UChicago Medicine 12th International Clinical Cancer Genomics Conference

MDS and AML: Implementation of Guideline-Driven Germline Genetic Eva…

Feat. L. Banaszak
17:01
Indy Hematology Review

R/R AML: Current, Emerging, and Targeted Therapies

Feat. R. Komrokji
17:51
Indy Hematology Review

Treatment of AML: Managing the Patient When Transplant Is Not an Opt…

Feat. H. Erba
28:02
University of Colorado Division of Hematology

2024 Updates in AML

Feat. C. McMahon
06:13
Insights from 2023 ASH Annual Meeting

FLT3-ITD Mutated AML: PROs From the QuANTUM-First Trial of Quizartin…

Feat. E. Oliva
29:38
Scripps Health

FLT3-Mutated AML: Advances in Frontline Treatment

Feat. N. Short
07:56
University of Miami Sylvester Comprehensive Cancer Center

Role of Mutations in AML: FLT3-ITD Mutation Confers Poor Prognosis b…

Feat. S. Venugopal
18:27
Insights from 2023 ASH Annual Meeting

FLT3-ITD Mutated AML: QuANTUM-First - Safety by Treatment Phase and …

Feat. H. Erba
22:30
Penn Medicine's 2024 Updates in Care of the Hematologic Malignancies Patient

Emerging Treatment Options for AML in 2024

Feat. A. Perl
22:37
Insights from 2023 ASH Annual Meeting

AML and MDS Highlights & Key Takeaways

Feat. T. Badar
10:32
Insights from 2023 ASH Annual Meeting

FLT3-ITD Mutated AML: Quizartinib, Venetoclax, & Decitabine Trip…

Feat. M. Yilmaz